HK Stock Market Move | WUXI BIO (02269) increased by more than 4%. Signed 69 comprehensive projects in the first four months, maintaining the expected revenue growth of up to 17% for this year.

WUXI BIO (02269) rose more than 4%, as of the time of writing, up by 4.26% to 34.76 Hong Kong dollars, with a turnover of 1.323 billion Hong Kong dollars. On the news front, on the evening of May 31, WUXI BIO announced that as of April 30 this year, the company has signed 69 new comprehensive projects, with about two-thirds coming from the American and European markets. The company maintains its guidance for annual revenue growth of 13% to 17% this year. Excluding the impact of exchange rate fluctuations, revenue growth is expected to reach 16% to 20%. WUXI BIO stated that with the advantage of a global CRDMO (Contract Research, Development, and Manufacturing) platform and a continuously expanding customer base, the company remains confident in its future growth prospects. Management expects a compound annual growth rate of 20% for revenue in the next three years.